Healius's Collapse Is Dragging Down Sentiment Across Pathology
A Fair Work wage decision and weak GP volumes kept triggering downgrades, even as core pathology revenue growth outpaced the broader industry.
28 Aug 2026 · 2 min read
In short
Healius collapsed from around $1.00 to as low as $0.34 in 2026 as a Fair Work wage decision, weaker GP pathology volumes and no government indexation relief repeatedly blew out cost expectations.
The company's Core Pathology revenue actually grew 3.5% year on year, outperforming softer industry-wide Medicare trends, yet Spheria Asset Management calls the market's reaction to its first-half result overly negative.
Investors Mutual Limited notes Healius's struggles have weighed on sentiment toward the entire pathology sector, including rival Australian Clinical Labs.
Healius collapsed from around $1.00 to as low as $0.34 through 2026 as a Fair Work wage decision, weaker GP pathology volumes and the absence of government indexation funding relief repeatedly blew out cost expectations, even after the company had already used proceeds from selling its Lumus Imaging radiology business to pay a large special dividend.
A radiology sale, then a mixed pathology recovery
First Samuel said that since the sale of Lumus Imaging on 1 May 2025, which delivered $822 million in cash proceeds and a fully franked special dividend of 41.3 cents per share, the performance of the remaining pathology business has been mixed, with improvements in operational efficiency, labour savings and technology rollout offset by a Fair Work Australia decision mandating a large wage increase.
A weak result draws an overly negative reaction
Spheria Asset Management said the stock fell around 24 percent following its first-half FY26 result, and while the bottom-line result was weak as anticipated, the market reaction appeared overly negative and surprising given Core Pathology revenue grew 3.5 percent year on year on volume growth of 1.2 percent, outperforming softer industry-wide Medicare trends. Blackwattle Investment Partners said Healius missed consensus at both the EBITDA and EBIT lines on higher depreciation and amortisation, putting it firmly in what it called the second-half club, with a real risk of another earnings miss, even as restructuring efforts showed up in the cost base through lab rationalisation, collection centre closures and the removal of 400 employees, with cost savings largely complete but yet to fully annualise.
Although the bottom-line result was weak (as anticipated), the market reaction appeared overly negative and surprising. Core Pathology revenue grew 3.5% YoY, driven by volume growth of +1.2%, outperforming softer industry trends.
— Spheria Asset Management, Monthly Report, February 2026
Worse GP volumes and no government relief compound the pain
Ellerston Capital said Healius was a major negative contributor in April, down 9.8 percent, and again in May, down 32.7 percent, after worse than expected GP pathology volumes in April resulted in a 4.1 percent EBITDA downgrade, with no indexation funding relief forthcoming from the federal government.
Worse than expected GP pathology volumes in April resulted in a 4.1% EBITDA downgrade, with no indexation funding relief from the Federal Government.
— Ellerston Capital, Monthly Report, May 2026
Healius's struggles are dragging down the whole sector's sentiment
Investors Mutual Limited said the market struggles to believe the third-largest pathology player, Australian Clinical Labs, can run meaningfully higher margins than the two largest players, and that ongoing struggles at Healius specifically have weighed on sentiment toward the whole pathology sector, including its rival.
What fund managers say they are watching next is whether the Fair Work wage increase and lack of government indexation relief continue pressuring margins, GP pathology volume trends, delivery of the largely complete cost savings program as it fully annualises into FY27, and whether Healius's struggles keep weighing on sentiment across the broader pathology sector.
Questions
Why did Healius's share price collapse through 2026?
Healius collapsed as a Fair Work Australia decision mandating a large wage increase, weaker GP pathology volumes, and a lack of government indexation funding relief repeatedly triggered earnings downgrades throughout the year.
Was Healius's underlying pathology business actually performing poorly?
Not entirely. Spheria Asset Management notes Core Pathology revenue grew 3.5% year on year, outperforming softer industry-wide Medicare trends, even as the market's reaction to the first-half result was described as overly negative.
Has Healius's collapse affected other pathology companies?
Yes. Investors Mutual Limited notes ongoing struggles at Healius have weighed on sentiment toward the entire pathology sector, including rival Australian Clinical Labs, even though that company's fundamentals differ.
9 managers, 21 comments, with each manager's latest recorded position.
See HLS